氨基乙醛乙烷二硫代缩醛 | 104910-53-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二硫杂环戊烷
• 中文名称: 氨基乙醛乙烷二硫代缩醛
• 英文名称: aminoacetaldehyde ethane dithioacetal
• 英文别名: C-[1,3]dithiolan-2-yl-methylamine；1,3-dithiolan-2-yl-methylamine；1,3-dithiolan-2-ylmethylamine；1,3-dithiolan-2-methylamine；1,3-dithiolan-2-ylmethanamine
• CAS: 104910-53-4
• 化学式: C₄H₉NS₂
• mdl: MFCD19204165
• 分子量: 135.254
• InChiKey: HXKZAVMODXTMAI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  7
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  76.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  氨基乙醛乙烷二硫代缩醛 、 2-溴-1,1-二甲氧基乙烷 以8%的产率得到
  参考文献：
  名称：

  LOPEZ, APARICIO F. J.;ZORRILLA, BENITEZ F.;ALVAREZ-MANZANEDA, ROLDAN E. J+, AN. QUIM. C/REAL SOC. ESP. QUIM., 84,(1988) N, C. 277-284

  摘要：

  DOI：
• 作为产物：
  描述：

  1,2-乙二硫醇 、 氨基乙醛缩二乙醇 在 对甲苯磺酸 作用下， 以 甲苯 为溶剂， 反应 6.0h， 生成 氨基乙醛乙烷二硫代缩醛
  参考文献：
  名称：

  [EN] FURANOPYRIMIDINES
  [FR] FURANOPYRIMIDINES

  摘要：

  公开号：

  WO2006004658A3

文献信息

• Furanopyridine derivatives and methods of use
  申请人：Nunes J. Joseph

  公开号：US20060046977A1

  公开（公告）日：2006-03-02

  The present invention relates to furanopyridine compounds having the general Formula I: and stereoisomers, tautomers, solvates, pharmaceutically acceptable salts and derivatives, and prodrugs thereof. The invention also includes pharmaceutical compositions comprising a compound of Formula I, methods of modulating Lck and ACK-1 enzymes and of treating various related diseases and conditions, including inflammation, inhibition of T cell activation, proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma, thymoma, just to name a few, in a mammal, comprising administering to the mammal a therapeutically effective amount a compound of Formula I, as described above, and methods of manufacturing medicaments comprising the compound of Formula I.

  本发明涉及具有一般式I的呋喃吡啶化合物，以及其立体异构体、互变异构体、溶剂合物、药学上可接受的盐和衍生物，以及其前药。该发明还包括包含一种式I化合物的药物组合物，调节Lck和ACK-1酶的方法，以及治疗各种相关疾病和症状的方法，包括炎症、T细胞激活抑制、增殖、关节炎、器官移植、缺血或再灌注损伤、心肌梗死、中风、多发性硬化、炎症性肠病、克罗恩病、狼疮、过敏、1型糖尿病、牛皮癣、皮炎、哈希蒙氏甲状腺炎、干燥综合征、自身免疫性甲状腺功能亢进症、艾迪生病、自身免疫性疾病、肾小球肾炎、过敏性疾病、哮喘、花粉热、湿疹、癌症、结肠癌、胸腺瘤等，在哺乳动物体内，包括向哺乳动物体内施用上述式I化合物的治疗有效量，并制备包含式I化合物的药物的方法。
• Aminomethyl-substituted thiazolobenzimidazole derivative
  申请人：Itahana Hirotsune

  公开号：US20050148642A1

  公开（公告）日：2005-07-07

  This invention relates to the provision of novel aminomethyl-substituted thiazolobenzimidazole derivatives represented by the following general formula (I) or a salt thereof. The aforementioned derivative or a salt thereof has a metabotropic glutamate receptor action and excellent oral activity and is therefore useful as a medicament. (In the formula, R 1 : an oxygen-containing saturated hetero ring or the like, Alk 1 : a lower alkylene, m: 0 or 1, Alk 2 : a lower alkylene which may be substituted with oxo group, n: 0 or 1, X: a bond, O, S or NR 5 , R 3 : H or the like, and R 2 , R 4 , R 5 , R 6 and R 7 : the same or different from one another and each represents H or the like. Provided that R 3 does not represent a lower alkyl or a halogeno-lower alkyl when X is a bond and n is 1. Also, R 4 represents a group other than Me when m is 1, R 1 is OH or OMe and Alk 1 is a C 1-3 alkylene, and further 1) when X is a bond, n is 1 and R 3 is H, or 2) when X is a bond, n is 0 and R 3 is cyclohexane.)

  本发明涉及提供以下一般式（I）或其盐所表示的新型氨甲基取代噻唑苯并咪唑衍生物。上述衍生物或其盐具有代谢型谷氨酸受体作用和良好的口服活性，因此可用作药物。其中，R1：含氧饱和杂环或类似物，Alk1：较低的烷基，m：0或1，Alk2：较低的烷基，可以用氧代基取代，n：0或1，X：键，O，S或NR5，R3：H或类似物，R2，R4，R5，R6和R7：相同或不同，每个代表H或类似物。前提是当X是键且n为1时，R3不代表较低的烷基或卤代较低的烷基。此外，当m为1时，R4代表除Me以外的基团，R1为OH或OMe，Alk1为C1-3烷基，进一步1）当X是键，n为1且R3为H时，或2）当X是键，n为0且R3为环己烷时。
• Furanopyrimidines
  申请人：Buchanan Laird John

  公开号：US20060040961A1

  公开（公告）日：2006-02-23

  The present invention relates to furanopyrimidine compounds having the general Formula I: and stereoisomers, tautomers, solvates, pharmaceutically acceptable salts and derivatives, and prodrugs thereof. The invention also includes pharmaceutical compositions comprising a compound of Formula I, methods of treating various diseases and conditions in a mammal, including inflammation, inhibition of T cell activation, proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma and thymoma, comprising administering to the mammal a therapeutically effective amount of a compound of Formula I. The invention also relates to methods of manufacturing medicaments, which comprise one or more compounds of Formula I.

  本发明涉及具有一般式I的呋喃嘧啶化合物及其立体异构体、互变异构体、溶剂化物、药学上可接受的盐和衍生物以及其前药。本发明还包括包含一种I式化合物的制药组合物，以及在哺乳动物中治疗各种疾病和病况的方法，包括炎症、抑制T细胞激活、增殖、关节炎、器官移植、缺血或再灌注损伤、心肌梗死、中风、多发性硬化症、炎症性肠病、克罗恩病、狼疮、过敏、1型糖尿病、牛皮癣、皮炎、桥本氏甲状腺炎、干燥综合症、自身免疫性甲状腺功能亢进症、Addison病、自身免疫性疾病、肾小球肾炎、过敏性疾病、哮喘、花粉热、湿疹、癌症、结肠癌和胸腺瘤的方法，包括向哺乳动物中投与一种I式化合物的治疗有效量。本发明还涉及制造药物的方法，其包括一种或多种I式化合物。
• Aminomethyl-substituted thiazolobenzimidazole compounds
  申请人：Astellas Pharma Inc.

  公开号：US07250429B2

  公开（公告）日：2007-07-31

  This invention relates to the provision of novel aminomethyl-substituted thiazolobenzimidazole derivatives represented by the following general formula (I) or a salt thereof. The aforementioned derivative or a salt thereof has a metabotropic glutamate receptor action and excellent oral activity and is therefore useful as a medicament. (In the formula, R1: an oxygen-containing saturated hetero ring or the like, Alk1: a lower alkylene, m: 0 or 1, Alk2: a lower alkylene which may be substituted with oxo group, n: 0 or 1, X: a bond, O, S or NR5, R3: H or the like, and R2, R4, R5, R6 and R7: the same or different from one another and each represents H or the like. Provided that R3 does not represent a lower alkyl or a halogeno-lower alkyl when X is a bond and n is 1. Also, R4 represents a group other than Me when m is 1, R1 is OH or OMe and Alk1 is a C1-3 alkylene, and further 1) when X is a bond, n is 1 and R3 is H, or 2) when X is a bond, n is 0 and R3 is cyclohexane.)

  本发明涉及一种新型的氨甲基取代的噻唑苯并咪唑衍生物，其通式如下(I)，或其盐。上述衍生物或其盐具有代谢型谷氨酸受体作用和优异的口服活性，因此可用作药物。（在公式中，R1：氧含量饱和杂环等，Alk1：低级烷基，m：0或1，Alk2：可能被氧代基取代的低级烷基，n：0或1，X：键，O，S或NR5，R3：H或类似物，R2，R4，R5，R6和R7：相同或不同，且每个代表H或类似物。前提是当X为键且n为1时，R3不代表低级烷基或卤代低级烷基。此外，当m为1，R1为OH或OMe，Alk1为C1-3烷基时，R4代表Me以外的基团，且进一步1）当X为键，n为1且R3为H时，或2）当X为键，n为0且R3为环己烷时，R4代表其他基团。）
• AMINOMETHYL-SUBSTITUTED THIAZOLOBENZIMIDAZOLE DERIVATIVE
  申请人：Astellas Pharma Inc.

  公开号：EP1486501B1

  公开（公告）日：2008-09-10